Results from a Phase I clinical trial for the study of the first new oral polio vaccine in 50 years have shown promise, say researchers. The vaccine has been designed to be incapable of evolving the ability to cause disease in humans.
The study is supported by the Bill and Melinda Gates Foundation and led by University of California San Francisco virologist Dr Raul Andino and Dr Andrew Macadam, from the UK’s National Institute for Biological Standards and Control (NIBSC).
In a 2017 study, Andino and colleagues discovered that in every vaccine-derived polio outbreak they studied, the virus had used the same three evolutionary steps to mutate from a harmless vaccine into a regional menace.
In their new study, Andino, Macadam and colleagues redesigned the vaccine to ensure that it is incapable of following this three-step pathway to re-evolve virulence...
Full text at GMPnews.Net